Table 2 Site-specific standardized incidence ratios and excess absolute risks of SPMs in patients with previous OAL
From: Second primary malignancies after ocular adnexal lymphoma diagnosis
Second Cancer Site | O | O/E | 95% CI | EAR** |
|---|---|---|---|---|
All Sites | 279 | 1.20* | 1.07–1.35 | 30.56 |
All Sites excluding Non-Melanoma Skin | 274 | 1.19* | 1.05–1.34 | 27.98 |
All Solid Tumors | 193 | 0.94 | 0.82–1.09 | −7.46 |
Oral Cavity and Pharynx | 2 | 0.39 | 0.05–1.42 | −1.99 |
Digestive System | 48 | 0.99 | 0.73–1.31 | −0.3 |
Respiratory System | 35 | 0.96 | 0.67–1.33 | −1.01 |
Bones and Joints | 1 | 4.8 | 0.12–26.73 | 0.51 |
Soft Tissue including Heart | 1 | 0.84 | 0.02–4.68 | − 0.12 |
Skin excluding Basal and Squamous | 11 | 1.17 | 0.58–2.09 | 1.01 |
Melanoma of the Skin | 6 | 0.71 | 0.26–1.55 | −1.56 |
Other Non-Epithelial Skin | 5 | 4.91* | 1.59–11.46 | 2.58 |
Breast | 19 | 0.62* | 0.37–0.96 | −7.68 |
Female Breast | 19 | 0.62* | 0.37–0.97 | −13.29 |
Male Breast | 0 | 0 | 0–14.22 | −0.39 |
Female Genital System | 12 | 0.99 | 0.51–1.73 | − 0.16 |
Male Genital System | 38 | 1.07 | 0.75–1.46 | 3.51 |
Urinary System | 24 | 1.22 | 0.78–1.81 | 2.75 |
Urinary Bladder | 12 | 0.94 | 0.48–1.64 | −0.52 |
Kidney and Renal Pelvis | 12 | 1.89 | 0.98–3.3 | 3.65 |
Renal Pelvis, Ureter, and Other Urinary Organs | 0 | 0 | 0–3.12 | −0.77 |
Kidney | 12 | 2.08* | 1.08–3.64 | 4.03 |
Renal Pelvis | 0 | 0 | 0–6.24 | −0.38 |
Ureter | 0 | 0 | 0–9.7 | −0.25 |
Other Urinary Organs | 0 | 0 | 0–17.37 | −0.14 |
Eye and Orbit | 0 | 0 | 0–10.64 | −0.22 |
Brain and Other Nervous System | 2 | 0.87 | 0.11–3.15 | −0.19 |
Brain | 0 | 0 | 0–1.68 | −1.42 |
Cranial Nerves/Other Nervous System | 2 | 19.90* | 2.41–71.89 | 1.23 |
Endocrine System | 5 | 1.81 | 0.59–4.22 | 1.45 |
All Lymphatic and Hematopoietic Diseases | 75 | 3.64* | 2.86–4.56 | 35.17 |
Lymphoma | 55 | 5.30* | 4–6.9 | 28.87 |
Hodgkin’s | 3 | 5.64* | 1.16–16.47 | 1.6 |
HL - Nodal | 3 | 5.86* | 1.21–17.13 | 1.61 |
HL - Extranodal | 0 | 0 | 0–180.57 | −0.01 |
Non-Hodgkin’s | 52 | 5.29* | 3.95–6.93 | 27.27 |
NHL - Nodal | 23 | 3.51* | 2.22–5.26 | 10.63 |
NHL - Extranodal | 29 | 8.84* | 5.92–12.7 | 16.64 |
Myeloma | 5 | 1.46 | 0.48–3.42 | 1.02 |
Leukemia | 15 | 2.20* | 1.23–3.62 | 5.28 |
Lymphocytic Leukemia | 6 | 1.76 | 0.65–3.83 | 1.67 |
Acute Lymphocytic Leukemia | 0 | 0 | 0–19.88 | −0.12 |
Chronic Lymphocytic Leukemia | 6 | 1.98 | 0.73–4.32 | 1.92 |
Other Lymphocytic Leukemia | 0 | 0 | 0–18.31 | −0.13 |
Non-Lymphocytic Leukemia | 9 | 2.63* | 1.2–5 | 3.61 |
Acute Non-Lymphocytic Leukemia (ANLL) | 7 | 3.17* | 1.28–6.54 | 3.1 |
Myeloid and Monocytic Leukemia | 9 | 3.03* | 1.39–5.75 | 3.9 |
Acute Myeloid Leukemia | 6 | 3.17* | 1.16–6.91 | 2.66 |
Acute Monocytic Leukemia | 1 | 9.62 | 0.24–53.57 | 0.58 |
Chronic Myeloid Leukemia | 1 | 1.14 | 0.03–6.38 | 0.08 |
Other Myeloid/Monocytic Leukemia | 1 | 9.96 | 0.25–55.5 | 0.58 |
Other Leukemia | 0 | 0 | 0–8.18 | −0.29 |
Other Acute Leukemia | 0 | 0 | 0–17.57 | −0.14 |
Aleukemic, Subleukemic and NOS | 0 | 0 | 0–15.29 | −0.16 |
Mesothelioma | 0 | 0 | 0–5.98 | −0.4 |
Kaposi Sarcoma | 0 | 0 | 0–19.49 | −0.12 |
Miscellaneous | 6 | 1.07 | 0.39–2.34 | 0.27 |